The litany of failed experimental therapies for amyotrophic lateral sclerosis (ALS) added another verse today, after Apellis Pharma gave up on Sobi-partnered candidate peg
Apellis' chances of getting regulatory approval for pegcetacoplan, its drug candidate for sight-robbing disease geographic atrophy (GA), may have been heightened by new follow-up data from
Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US.